Gazyva (obinutuzumab) / Roche, Biogen 
Welcome,         Profile    Billing    Logout  
 23 Diseases   162 Trials   162 Trials   4758 News 


«12...1819202122232425262728...6061»
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen
    Clinical, Journal:  Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma. (Pubmed Central) -  Jan 29, 2022   
    Since no improvement was observed with standard of care (including remdesivir), the possibility of hyperimmune plasma infusion was discussed...Within twelve hours cough and fever disappeared, and oxygen at rest was discontinued. The patient was discharged 5 days later, and nasopharyngeal swabs resulted negative 16 days after discharge.
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  The future of antibody therapy in Chronic Lymphocytic Leukemia. (Pubmed Central) -  Jan 27, 2022   
    In this review, we highlight the important role that anti-CD20 antibody therapy has had in the field of CLL, both when used with chemotherapy and in combination with targeted therapy, as well as the current studies that are further exploring this treatment paradigm in the modern era. While anti-CD20 antibodies have played a pivotal role in the treatment of CLL, additional studies will be required to determine the optimal application of these therapies in combination with targeted therapy.
  • ||||||||||  Benlysta (belimumab) / GSK, Lupkynis (voclosporin) / Aurinia Pharma, Otsuka, Gazyva (obinutuzumab) / Roche, Biogen
    Review, Journal:  Induction and Maintenance Treatment of Lupus Nephritis: A Comprehensive Review of Meta-Analyses. (Pubmed Central) -  Jan 26, 2022   
    This review aggregates evidence of therapy for clinicians and sheds light on comparative efficacies of alternative LN treatments. As more promising agents are entering the market, such as voclosporin, belimumab, and obinutuzumab, LN management might undergo significant changes during the next years.
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal, IO biomarker:  Calcium channel blockers impair the antitumor activity of anti-CD20 monoclonal antibodies by blocking EGR-1 induction. (Pubmed Central) -  Jan 21, 2022   
    These results reveal EGR-1 as a key mediator of the direct cytotoxic activity of anti-CD20 mAbs and provide a rationale to evaluate EGR-1 expression as a new biomarker to predict response to anti-CD20 treatment. In addition, our findings show that calcium influx is required for anti-CD20-mediated tumor cell death and suggest that simultaneous administration of calcium channel blocking agents could be deleterious in patients receiving anti-CD20 based immunotherapy.
  • ||||||||||  Vistide (cidofovir) / Gilead
    BK POLYOMAVIRUS NEPHRITIS IN A LOW RISK, NATIVE KIDNEY (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_775;    
    This case highlights that BK nephropathy may develop in the native kidney other than HSCT. Chronic lymphopenia and hypogammaglobinemia likely predisposed our patient despite his ongoing infusion of IVIG.
  • ||||||||||  lenalidomide / Generic mfg.
    Review, Journal:  Early Progressing Follicular Lymphoma. (Pubmed Central) -  Jan 20, 2022   
    Ongoing trials seek to identify the optimal management of these patients, and data from bispecific antibodies and CAR T cell therapies is forthcoming. With ongoing research efforts, hope remains that we are closer to being able to predict which patients will experience early progressing follicular lymphoma and have an improved management plan for those who do in order to improve survival outcomes.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
    Trial completion date, Trial termination, Trial primary completion date:  VENOBI-CNS: Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma (clinicaltrials.gov) -  Jan 19, 2022   
    P1,  N=4, Terminated, 
    With ongoing research efforts, hope remains that we are closer to being able to predict which patients will experience early progressing follicular lymphoma and have an improved management plan for those who do in order to improve survival outcomes. Trial completion date: Mar 2024 --> Nov 2021 | Suspended --> Terminated | Trial primary completion date: Jul 2023 --> Nov 2021; low recruitment
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
    Enrollment change, Trial termination:  OPERA PLRG-10: Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse (clinicaltrials.gov) -  Jan 13, 2022   
    P2,  N=1, Terminated, 
    Our findings compare favourably with available therapies and support future investigation of Pola-G-Len in a larger patient population. N=60 --> 1 | Recruiting --> Terminated; Very slow recruitment due to lack of relapse in the observed group of patients
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen
    Journal:  Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. (Pubmed Central) -  Jan 11, 2022   
    The combination of an easily expandable CIK cell effector population with a mAb already in clinical use establishes a tumor antigen-specific redirection strategy that can be rapidly translated into clinical practice, providing an effective therapeutic alternative for B-cell malignancies without any need for genetic modifications. Additionally, the approach can be potentially applied to an extremely vast array of different tumors by simply substituting the targeting mAb.
  • ||||||||||  FT516 / Fate Therap
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  FT516-101: FT516 in Subjects With Advanced Hematologic Malignancies (clinicaltrials.gov) -  Jan 11, 2022   
    P1,  N=234, Recruiting, 
    Active, not recruiting --> Completed N=72 --> 234 | Trial completion date: May 2026 --> May 2039 | Trial primary completion date: Jul 2021 --> May 2024
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Calquence (acalabrutinib) / AstraZeneca
    Journal, IO biomarker:  Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. (Pubmed Central) -  Jan 4, 2022   
    Moreover, the optimal sequencing of targeted therapies remains to be determined. A particular challenge of the next few years will be to identify alternative therapies for patients with BTK and BCL2 inhibitor double-refractory disease.
  • ||||||||||  rhIL-15 / National Cancer Institute
    Trial completion, Trial completion date, Trial primary completion date:  Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia (clinicaltrials.gov) -  Jan 4, 2022   
    P1,  N=1, Completed, 
    A particular challenge of the next few years will be to identify alternative therapies for patients with BTK and BCL2 inhibitor double-refractory disease. Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Dec 2021 | Trial primary completion date: Jun 2023 --> Dec 2021
  • ||||||||||  Columvi (glofitamab) / Roche, Lunsumio (mosunetuzumab) / Roche, Biogen
    Enrollment open, CAR T-Cell Therapy:  CAR-T Followed by Bispecific Antibodies (clinicaltrials.gov) -  Jan 4, 2022   
    P2,  N=42, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Dec 2021 | Trial primary completion date: Jun 2023 --> Dec 2021 Not yet recruiting --> Recruiting